Publications
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
In recent years, the European Medicines Agency (EMA) has introduced several…
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may…
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to…
The broader economic benefits of COVID-19 vaccination
13 October 2025
Why investigating the economic case for ongoing COVID-19 vaccination matters…
Insights
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
14 October 2025
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at…
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
The following is an extract from OHE’s written submission to parliament…
Environmental sustainability in the NHS 10 Year Health Plan: The need for green
29 September 2025
This is the second in a series of blogs about how the proposals in the recently…
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
24 September 2025
The next stop in our around the world in HTAs adventure is Saudi Arabia. This…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
Achieving Accelerated Patient Access to Cancer Care in Europe
In recent years, the European Medicines Agency (EMA) has introduced several accelerated pathways (APs) to enable earlier…
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping…
Drug Development/R&D
OHE’s submission to a parliamentary inquiry on UK drug shortages
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising…
The Trump Administration’s US Drug Pricing Proposal – What will happen next?
This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most…
Digital Health
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and…
OHE’s submission for the DHSC’s next 10 years of planning
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation…
Prevention
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at the NHS 10 Year Health Plan, concluding that…
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.